Antibody data
- Antibody Data
- Antigen structure
- References [3]
- Comments [0]
- Validations
- Western blot [1]
- Immunocytochemistry [1]
- Immunohistochemistry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 14-9096-82 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- Osteopontin Monoclonal Antibody (2F10), eBioscience™
- Antibody type
- Monoclonal
- Antigen
- Other
- Description
- Description: The 2F10 monoclonal antibody recognizes human osteopontin (OPN), a secreted glycophosphoprotein expressed by multiple cell types, including leukocytes, fibroblasts, dendritic cells, macrophages, myoblasts, bone-forming cells, and epithelial cells. OPN is an extracellular matrix protein with multiple roles, including bone resorption and calcification, immune system regulation, wound healing, and tumorigenesis. Thrombin cleavage of OPN allows binding of integrin receptors, expressed by immune cells, and subsequent modulation of cell adhesion, migration, and survival. OPN is expressed in bones, teeth, placenta, blood vessels, kidney, and various tumors. Osteopontin has been identified as a potential therapeutic target in the treatment of autoimmune disease, cancer metastasis, bone mineralization diseases, and osteoporosis. Applications Reported: This 2F10 antibody has been reported for use in western blotting, immunohistochemical staining of formalin-fixed paraffin embedded tissue sections, and immunocytochemistry. Applications Tested: This 2F10 antibody has been tested by immunohistochemistry of formalin-fixed paraffin embedded human tissue using either low or high pH antigen retrieval and can be used at less than or equal to 5 µg/mL. This 2F10 antibody has been tested by immunocytochemistry of either methanol-fixed or formaldehyde-fixed and permeabilized human cells and can be used at less than or equal to 10 µg/mL. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest. Purity: Greater than 90%, as determined by SDS-PAGE. Aggregation: Less than 10%, as determined by HPLC. Filtration: 0.2 µm post-manufacturing filtered.
- Reactivity
- Human
- Host
- Mouse
- Isotype
- IgG
- Antibody clone number
- 2F10
- Vial size
- 100 µg
- Concentration
- 0.5 mg/mL
- Storage
- 4° C
Submitted references Osteopontin expression by CD103- dendritic cells drives intestinal inflammation.
Association of osteopontin and cyclooxygenase-2 expression with breast cancer subtypes and their use as potential biomarkers.
Development of fragment-specific osteopontin antibodies and ELISA for quantification in human metastatic breast cancer.
Kourepini E, Aggelakopoulou M, Alissafi T, Paschalidis N, Simoes DC, Panoutsakopoulou V
Proceedings of the National Academy of Sciences of the United States of America 2014 Mar 4;111(9):E856-65
Proceedings of the National Academy of Sciences of the United States of America 2014 Mar 4;111(9):E856-65
Association of osteopontin and cyclooxygenase-2 expression with breast cancer subtypes and their use as potential biomarkers.
Thorat D, Sahu A, Behera R, Lohite K, Deshmukh S, Mane A, Karnik S, Doke S, Kundu GC
Oncology letters 2013 Dec;6(6):1559-1564
Oncology letters 2013 Dec;6(6):1559-1564
Development of fragment-specific osteopontin antibodies and ELISA for quantification in human metastatic breast cancer.
Plumer A, Duan H, Subramaniam S, Lucas FL, Miesfeldt S, Ng AK, Liaw L
BMC cancer 2008 Jan 31;8:38
BMC cancer 2008 Jan 31;8:38
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot was performed using Anti-Osteopontin Monoclonal Antibody (2F10), eBioscience™(Product # 14-9096-82) and a 75kDa band corresponding to Osteopontin was observed in Hep G2 and MCF-7 cell line treated with Protein Transport Inhibitor (PTI, 1X for 4 hr) as compared to IMR-32 and Jurkat cell line treated with same inhibitor. Whole cell extracts (30 µg lysate) of Hep G2 (Lane 1), Hep G2 +PTI (1X for 4 hr) (Lane 2), MCF-7 (Lane 3), MCF-7+PTI (1X for 4 hr) (Lane 4), IMR-32 ( Lane 5), IMR-32+ PTI (1X for 4 hr) (Lane 6), Jurkat (Lane 7) and Jurkat+ PTI (1X for 4 hr) ( Lane 8) were electrophoresed using NuPAGE™ 4-12% Bis-Tris Protein Gel (Product # NP0322BOX). Resolved proteins were then transferred onto a Nitrocellulose membrane (Product # IB23001) by iBlot® 2 Dry Blotting System (Product # IB21001). The blot was probed with the primary antibody (1ug/ml) and detected by chemiluminescence with Goat anti-Mouse IgG (H+L) Superclonal™ Recombinant Secondary Antibody, HRP (Product # A28177,1:4000 dilution) using the iBright FL 1000 (Product # A32752). Chemiluminescent detection was performed using Novex® ECL Chemiluminescent Substrate Reagent Kit (Product # WP20005).
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunocytochemistry of methanol-fixed MCF7 cells using 10 µg/mL of Anti-Human Osteopontin Purified, followed by F (ab')2 Anti-Mouse IgG eFluor® 570.Nuclei are stained with DAPI.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemistry of formalin-fixed paraffin embedded human infiltrating ductile carcinoma tissue using 5 µg/mL of Anti-Human Osteopontin Purified, followed by Anti-Mouse IgG Biotin, Streptavidin HRP, and DAB visualization.Nuclei are counterstained with hematoxylin.